Advertisement

Transforming Growth Factor-β

  • Harold L. Moses
  • Edward B. Leof

Abstract

Transforming growth factor, type β (TGF-β) was first described by its ability to stimulate mouse embryo-derived AKR-2B cells (Moses et al. 1981) and rat NRK cells to grow in soft agar (Roberts et al. 1981). (The latter cells also required the addition of epidermal growth factor, EGF.) Subsequent studies have shown that TGF-β functions as a growth stimulator only for certain fibroblastic cells, possibly through an indirect mechanism involving the induction of endogenous growth-factor synthesis resulting in autocrine growth (Leof et al. 1986). In fact, TGF-β is a growth inhibitor for most cell types tested (Moses et al. 1985a and unpublished observations). Its growth-inhibitory properties, or those of a closely related molecule, were described by Holley and co-workers several years before its growth-stimulatory effects were discovered (Holley et al. 1978; Tucker et al. 1984a). This review discusses the possible mechanism of growth stimulation and growth inhibition by TGF-β and the possible role of this factor in neoplastic transformation.

Keywords

Transform Growth Factor Soft Agar Chicken Embryo Fibroblast Autocrine Stimulation Human Foreskin Keratinocytes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB (1983) Transforming growth factor-β in human platelets: Identification of a major storage site, purification and characterization. J Biol Chem 258: 7155–7160PubMedGoogle Scholar
  2. Carr BI, Hayashi I, Branum EL, Moses HL (1986) Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type-β-transforming growth factor. Cancer Res 46: 2330–2334PubMedGoogle Scholar
  3. Childs C, Proper JA, Tucker RF, Moses HL (1982) Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA 79: 5312–5316PubMedCrossRefGoogle Scholar
  4. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV (1985) Human transforming growth factor-β cDNA sequence and expression in tumor cell lines. Nature 316: 701–705PubMedCrossRefGoogle Scholar
  5. Frolik CA, Wakefield LM, Smith DM, Sporn MB (1984) Characterization of a membrane receptor for transforming growth factor-β in normal rat kidney cells. J Biol Chem 259: 10995–11000PubMedGoogle Scholar
  6. Goustin AS, Leof EB, Shipley GD, Moses HL (1986) Perspectives in Cancer Research: Growth factors and cancer. Cancer Res 46: 1015–1029PubMedGoogle Scholar
  7. Holley RW, Armour R, Baldwin JH (1978) Density-dependent regulation of growth of BSC-1 cells in cell culture: Growth inhibitors formed by the cells. Proc Natl Acad Sci USA 75: 1864–1866PubMedCrossRefGoogle Scholar
  8. Holley RW, Armour R, Baldwin JH, Greenfield S (1983) Preparation and properties of a growth inhibitor produced by kidney epithelial cells. Cell Biol Int Rep 7: 525–526CrossRefGoogle Scholar
  9. Laiho M, Saksela D, Keski-Oja J (1986) Transforming factor-β alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 164: 399–407PubMedCrossRefGoogle Scholar
  10. Lawrence DA, Pircher R, Kryceve-Martinerie C, Jullien P (1984) Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 121: 184–188PubMedCrossRefGoogle Scholar
  11. Lawrence DA, Pircher R, Jullien P (1985) Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions. Biochem Biophys Res Commun 133: 1016–1034CrossRefGoogle Scholar
  12. Leof EB, Proper JA, Goustin AS, Shipley GD, DiCorleto PE, Moses HL (1986) Induction of c-sis mRNA and activity similar to platelet-derived growth factor-like activity by transforming growth factor, type-β: A proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci USA 83: 2453–2457PubMedCrossRefGoogle Scholar
  13. Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying S-Y, Guillemin R, Niall H, Seeburg PH (1985) Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β. Nature 318: 659–663PubMedCrossRefGoogle Scholar
  14. Massague J (1985) Subunit structure of a high-affinity receptor for type β-transforming growth factor: evidence for a disulfide-linked glycosylated receptor complex. J Biol Chem 260: 7059–7066PubMedGoogle Scholar
  15. Massague J, Kelly B, Mottola C (1985) Stimulation by insulin-like growth factors is required for cellular transformation by type-β-transforming growth factor. J Biol Chem 260: 4551–4554PubMedGoogle Scholar
  16. Moses HL, Branum EB, Proper JA, Robinson RA (1981) Transforming growth factor production by chemically transformed cells. Cancer Res 41: 2842–2848PubMedGoogle Scholar
  17. Moses HL, Tucker RF, Leof EB, Coffey RJ Jr, Halper J, Shipley GD (1985a) Type-β transforming growth factor is a growth stimulator and a growth inhibitor. In: Feramisco J, Ozanne B, Stiles C (eds) Cancer cells: Growth factors and transformation. Cold Spring Harbor Press, New York, pp 65–71Google Scholar
  18. Moses HL, Shipley GD, Leof EB, Halper J, Coffey RJ Jr, Tucker RF (1985b) Transforming growth factors. In: Boynton AL, Leffert HL (eds) Control of animal cell proliferation. Academic Press, New York, (in press)Google Scholar
  19. Rizzino A (1984) Behavior of transforming growth factors in serum-free media: An improved assay for transforming growth factors. In Vitro 20: 815–822PubMedCrossRefGoogle Scholar
  20. Roberts AB, Sporn MB (1985) Transforming growth factors. In: Cancer surveys, vol. 4. Oxford Univ Press, Oxford, England, pp 683–705Google Scholar
  21. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB (1981) New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 78: 5339–5343PubMedCrossRefGoogle Scholar
  22. Shipley GD, Tucker RF, Moses HL (1985) Type-β-transforming growth factor/growth inhibitor stimulates entry of monolayer cultures of AKR-2B cells into S phase after a prolonged prereplicative interval. Proc Natl Acad Sci USA 82: 4147–4151PubMedCrossRefGoogle Scholar
  23. Shipley CD, Pittelkow MR, Wille JJ Jr, Scott RE, Moses HL (1986) Reversible inhibition of normal human prokeratinocyte proliferation by type-β-transforming growth factor/growth inhibitor in serum-free medium. Cancer Res 46: 2068–2071PubMedGoogle Scholar
  24. Tucker RF, Shipley GD, Moses HL, Holley RW (1984a) Growth inhibitor from BSC-1 cells closely related to the platelet type-β-transforming growth factor. Science 226: 705–707PubMedCrossRefGoogle Scholar
  25. Tucker RF, Branum EL, Shipley GD, Ryan RJ, Moses HL (1984b) Specific binding to cultured cells of 125I-labelled type-β-transforming growth factor from human platelets. Proc Natl Acad Sci USA 81: 6757–6761PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • Harold L. Moses
  • Edward B. Leof

There are no affiliations available

Personalised recommendations